Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Cleveland, OH
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Columbus, OH
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Portland, OR
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Nashville, TN
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Dallas, TX
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Falls Church, VA
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Falls Church, VA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
mi
from
Mar del Plata,
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
mi
from
Mar del Plata,
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Via Christi Clinic
mi
from
Wichita, KA
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Via Christi Clinic
mi
from
Wichita, KA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Columbia University Medical Center
mi
from
New York, NY
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Treatment for Severe Inflammatory Acne Subjects
Efficacy and Safety of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Doxycycline in Severe Inflammatory Acne (Non-Nodulocystic) Subjects
Status: Enrolling
Updated:  10/30/2017
Galderma Laboratories, LP
mi
from
Fort Worth, TX
A Treatment for Severe Inflammatory Acne Subjects
Efficacy and Safety of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Doxycycline in Severe Inflammatory Acne (Non-Nodulocystic) Subjects
Status: Enrolling
Updated: 10/30/2017
Galderma Laboratories, LP
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Micro-Technique Sampling
An Exploratory Comparative Pilot Study to Identify the Most Appropriate Method for Microbial Consortia Sampling From the Skin-II
Status: Enrolling
Updated:  10/30/2017
Reliance Clinical Testing Services, Inc.
mi
from
Irving, TX
Micro-Technique Sampling
An Exploratory Comparative Pilot Study to Identify the Most Appropriate Method for Microbial Consortia Sampling From the Skin-II
Status: Enrolling
Updated: 10/30/2017
Reliance Clinical Testing Services, Inc.
mi
from
Irving, TX
Click here to add this to my saved trials
A Study of Secukinumab for the Treatment of Alopecia Areata
An Exploratory Study to Evaluate the Safety and Efficacy of Secukinumab in the Treatment of Extensive Alopecia Areata
Status: Enrolling
Updated:  11/2/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
A Study of Secukinumab for the Treatment of Alopecia Areata
An Exploratory Study to Evaluate the Safety and Efficacy of Secukinumab in the Treatment of Extensive Alopecia Areata
Status: Enrolling
Updated: 11/2/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Structural Analysis of Human Tissue
Structural Analysis of Human Tissue
Status: Enrolling
Updated:  11/2/2017
Wake Forest University School of Medicine, Department of Plastic & Reconstructive Surgery
mi
from
Winston-Salem, NC
Structural Analysis of Human Tissue
Structural Analysis of Human Tissue
Status: Enrolling
Updated: 11/2/2017
Wake Forest University School of Medicine, Department of Plastic & Reconstructive Surgery
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Status: Enrolling
Updated:  11/3/2017
Therapeutics Clinical Research
mi
from
San Diego, CA
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Status: Enrolling
Updated: 11/3/2017
Therapeutics Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Status: Enrolling
Updated:  11/3/2017
Altman Dermatology Associates
mi
from
Arlington Heights, IL
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Status: Enrolling
Updated: 11/3/2017
Altman Dermatology Associates
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Status: Enrolling
Updated:  11/3/2017
Shideler Clinical Research Center
mi
from
Carmel, IN
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Status: Enrolling
Updated: 11/3/2017
Shideler Clinical Research Center
mi
from
Carmel, IN
Click here to add this to my saved trials
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Status: Enrolling
Updated:  11/3/2017
The Indiana Clinical Trials Center, PC
mi
from
Plainfield, IN
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Status: Enrolling
Updated: 11/3/2017
The Indiana Clinical Trials Center, PC
mi
from
Plainfield, IN
Click here to add this to my saved trials
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Status: Enrolling
Updated:  11/3/2017
Minnesota Clinical Study Center
mi
from
Fridley, MN
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Status: Enrolling
Updated: 11/3/2017
Minnesota Clinical Study Center
mi
from
Fridley, MN
Click here to add this to my saved trials
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Status: Enrolling
Updated:  11/3/2017
DermResearch, Inc.
mi
from
Austin, TX
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Status: Enrolling
Updated: 11/3/2017
DermResearch, Inc.
mi
from
Austin, TX
Click here to add this to my saved trials
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Status: Enrolling
Updated:  11/3/2017
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Status: Enrolling
Updated: 11/3/2017
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Retrospective Study to Evaluate the Effectiveness of the Ulthera System
Retrospective Evaluation of the Ulthera System for Lifting and Tightening of the Face and Neck
Status: Enrolling
Updated:  11/10/2017
Dermatology Cosmetic Laser Associates
mi
from
San Diego, CA
A Retrospective Study to Evaluate the Effectiveness of the Ulthera System
Retrospective Evaluation of the Ulthera System for Lifting and Tightening of the Face and Neck
Status: Enrolling
Updated: 11/10/2017
Dermatology Cosmetic Laser Associates
mi
from
San Diego, CA
Click here to add this to my saved trials
Feasibility Study: Heavy Water Tissue Labeling Protocol
Feasibility Study: Determination of the Effect of Ultherapy® Treatment on the Rate of Collagen Synthesis in Normal Skin
Status: Enrolling
Updated:  11/10/2017
Sasaki Advanced Aesthetic Medical Center
mi
from
Pasadena, CA
Feasibility Study: Heavy Water Tissue Labeling Protocol
Feasibility Study: Determination of the Effect of Ultherapy® Treatment on the Rate of Collagen Synthesis in Normal Skin
Status: Enrolling
Updated: 11/10/2017
Sasaki Advanced Aesthetic Medical Center
mi
from
Pasadena, CA
Click here to add this to my saved trials
Lifting and Tightening of the Face and Neck Following an Increased Density Treatment
Evaluation of the Efficacy and Safety of the Ulthera® System for Lifting and Tightening of the Face and Neck Following an Increased Density Treatment.
Status: Enrolling
Updated:  11/10/2017
Laser & Skin Surgery Center of NY
mi
from
New York, NY
Lifting and Tightening of the Face and Neck Following an Increased Density Treatment
Evaluation of the Efficacy and Safety of the Ulthera® System for Lifting and Tightening of the Face and Neck Following an Increased Density Treatment.
Status: Enrolling
Updated: 11/10/2017
Laser & Skin Surgery Center of NY
mi
from
New York, NY
Click here to add this to my saved trials
Treatment of the Face and Neck With Lower Ulthera System Energy Settings
Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck With Lower Energy Settings
Status: Enrolling
Updated:  11/10/2017
Ulthera, Inc.
mi
from
Mesa, AZ
Treatment of the Face and Neck With Lower Ulthera System Energy Settings
Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck With Lower Energy Settings
Status: Enrolling
Updated: 11/10/2017
Ulthera, Inc.
mi
from
Mesa, AZ
Click here to add this to my saved trials
Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis
Dapsone Gel, 5% for Topical Treatment of Dermatitis Herpetiformis
Status: Enrolling
Updated:  11/15/2017
Vanderbilt University - One Hundred Oaks
mi
from
Nashville, TN
Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis
Dapsone Gel, 5% for Topical Treatment of Dermatitis Herpetiformis
Status: Enrolling
Updated: 11/15/2017
Vanderbilt University - One Hundred Oaks
mi
from
Nashville, TN
Click here to add this to my saved trials
Lifting and Tightening of the Face and Neck Utilizing the Ulthera® System
Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck
Status: Enrolling
Updated:  11/16/2017
Baumann Cosmetic and Research Institute
mi
from
Miami Beach, FL
Lifting and Tightening of the Face and Neck Utilizing the Ulthera® System
Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck
Status: Enrolling
Updated: 11/16/2017
Baumann Cosmetic and Research Institute
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Lifting and Tightening of the Face and Neck Utilizing the Ulthera® System
Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck
Status: Enrolling
Updated:  11/16/2017
Zel Skin and Laser Specialists
mi
from
Edina, MN
Lifting and Tightening of the Face and Neck Utilizing the Ulthera® System
Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck
Status: Enrolling
Updated: 11/16/2017
Zel Skin and Laser Specialists
mi
from
Edina, MN
Click here to add this to my saved trials
Lifting and Tightening of the Face in Subjects With Skin of Darker Color
Evaluation of the Ulthera® System for Obtaining Lift and Tightening of the Cheek Tissue and Improvement in Jawline Definition and Submental Skin Laxity in Patients With Fitzpatrick Skin Phototypes 3 Through 6
Status: Enrolling
Updated:  11/16/2017
Harris Aesthetics, LLC
mi
from
Chevy Chase, MD
Lifting and Tightening of the Face in Subjects With Skin of Darker Color
Evaluation of the Ulthera® System for Obtaining Lift and Tightening of the Cheek Tissue and Improvement in Jawline Definition and Submental Skin Laxity in Patients With Fitzpatrick Skin Phototypes 3 Through 6
Status: Enrolling
Updated: 11/16/2017
Harris Aesthetics, LLC
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Lifting and Tightening of the Face in Subjects With Skin of Darker Color
Evaluation of the Ulthera® System for Obtaining Lift and Tightening of the Cheek Tissue and Improvement in Jawline Definition and Submental Skin Laxity in Patients With Fitzpatrick Skin Phototypes 3 Through 6
Status: Enrolling
Updated:  11/16/2017
Dermatology, Cosmetic & Laser Surgery
mi
from
Rockville, MD
Lifting and Tightening of the Face in Subjects With Skin of Darker Color
Evaluation of the Ulthera® System for Obtaining Lift and Tightening of the Cheek Tissue and Improvement in Jawline Definition and Submental Skin Laxity in Patients With Fitzpatrick Skin Phototypes 3 Through 6
Status: Enrolling
Updated: 11/16/2017
Dermatology, Cosmetic & Laser Surgery
mi
from
Rockville, MD
Click here to add this to my saved trials
Ultherapy™ Treatment Following Sculptra® Treatment
Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck Following Sculptra® Treatment
Status: Enrolling
Updated:  11/16/2017
EpiCentre Park Lane
mi
from
Dallas, TX
Ultherapy™ Treatment Following Sculptra® Treatment
Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck Following Sculptra® Treatment
Status: Enrolling
Updated: 11/16/2017
EpiCentre Park Lane
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Birmingham, AL
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Fort Smith, AR
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Rogers, AR
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Rogers, AR
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Clovis, CA
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Clovis, CA
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Lomita, CA
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Lomita, CA
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Oceanside, CA
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Palmdale, CA
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Palmdale, CA
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Rolling Hills Estates, CA
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Rolling Hills Estates, CA
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
San Diego, CA
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Santa Monica, CA
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Stockton, CA
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Stockton, CA
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Boca Raton, FL
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Clearwater, FL
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Clearwater, FL
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Miami Lakes, FL
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Miami, FL
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Pensacola, FL
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Pensacola, FL
Click here to add this to my saved trials
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Tampa, FL
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials